Skip to main content

Table 6 Haplotype distribution in patients and controls and association with breast cancer risk

From: Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study

  

Cases

Controls

   
 

Haplotype

N

F

N

F

OR

95%CI

P χ2

 

AAGT

284

0.47

248

0.47

1

  

1

AAG C

72

0.12

63

0.12

0.99

0.68-1.45

0.92

 

G A CC

60

0.1

48

0.09

1.09

0.72-1.62

0.68

 

AA CC

54

0.09

42

0.08

1.12

0.72-1.73

0.65

 

G AG C

6

0.01

0

0

  

0.03*

 

Total

192

0.32

153

0.29

1.09

0.83-1.43

0.5

2

A G GT

66

0.11

53

0.1

1.08

0.72-1.62

0.68

 

AA C T

30

0.05

26

0.05

1.00

0.58-1.75

1

 

G A C T

24

0.04

26

0.05

0.80

0.45-1.44

0.46

 

A GC T

0

0

5

0.01

  

0.02*

 

G AGT

0

0

5

0.01

  

0.02*

 

Others

8

0.01

12

0.02

0.58

0.23-1.44

0.23

 

Total

128

0.21

127

0.24

0.88

0.65-1.18

0.4

 

Total

604

1

528

1

   
  1. The haplotype combining the predominant alleles was used as a reference. Group 1 was formed by any haplotype containing the rs5275 C allele and group 2 included all the other haplotypes. The haplotypes with less than 1% frequency (Others) are not listed. The impact on breast cancer risk was calculated for the two groups, considering the Odds Ratio (OR) and the 95% Confidence Interval (95%CI) P: Pearson P-value; N: Number of haplotypes. F: Frequency of haplotypes. * Fisher Exact Probability Test (two-tailed). OR was not calculated because of N = 0.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us